Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs 7,238
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Pipeline programs

Page 69 of 151

  1. IRSSP-001

    The George Institute

    Patients diagnosed with unresectable and / or metastatic locoregionally advanced squamous cell carcinoma of the oral cavity, oropharynx or hypopharynx or larynx secondary to Fanconi anemia.

    phase 2 small molecule active

    1 trial

  2. IRST100.42

    Istituto Gentili S.r.l.

    neuroendocrine tumors, soft tissue sarcoma

    phase 2 small molecule active

    1 trial

  3. IRST100.59

    Istituto Gentili S.r.l.

    Solid tumors

    phase 2 other active

    1 trial

  4. IRST100.60

    Istituto Gentili S.r.l.

    NET, Neuroendocrine Tumor, Other SSTR-positive tumours, NETs retreated with PRRT, Pheochromocytomas and paragangliomas, Bronchopulmonary and other NETs

    phase 2 other active

    1 trial

  5. IRST153.09

    Istituto Gentili S.r.l.

    Metastatic colorectal cancer

    phase 2 small molecule active

    1 trial

  6. IRST162.14

    Istituto Gentili S.r.l.

    Extensive-Stage Small-Cell Lung Cancer (ES SCLC)

    phase 2 small molecule active

    1 trial

  7. IRST185.04

    Istituto Gentili S.r.l.

    metastatic castration resistant prostate cancer (mCRPC), symptomatic bone-only metastatic castration resistant prostate cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  8. IRST191.05

    Istituto Gentili S.r.l.

    Glioblastoma

    phase 2 small molecule active

    1 trial

  9. IRST204.09

    Istituto Gentili S.r.l.

    Acute myeloid leukemia

    phase 2 small molecule active

    1 trial

  10. IRX4204

    IO Biotech

    Psoriasis

    phase 2 small molecule on hold

    1 trial

  11. ISA-HC-NK

    The George Institute

    Multiple myeloma

    phase 2 small molecule active

    1 trial

  12. ISA101b

    Regeneron UK Limited

    Squamous Cell Carcinoma of the Oropharynx

    phase 2 mab active

    2 trials

  13. ISATUXIMAB

    Pari Pharma GmbH

    Isatuximab in type I cryoglobulinaemia: A prospective pilot study

    phase 2 small molecule active

    1 trial

  14. ISIS 104838

    IONIS PHARMACEUTICALS INC

    Rheumatoid Arthritis

    phase 2 small molecule completed

    1 trial

  15. ISIS 113715

    IONIS PHARMACEUTICALS INC

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    5 trials

  16. ISIS 14803

    IONIS PHARMACEUTICALS INC

    Hepatitis C, Chronic

    phase 2 small molecule completed

    1 trial

  17. ISIS 14803-CS3

    IONIS PHARMACEUTICALS INC

    Hepatitis C, Chronic

    phase 2 small molecule completed

    1 trial

  18. ISIS 2503

    IONIS PHARMACEUTICALS INC

    Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  19. ISIS 301012

    IONIS PHARMACEUTICALS INC

    Hypercholesterolemia, Familial

    phase 2 small molecule completed

    1 trial

  20. ISIS 301012 or Placebo

    IONIS PHARMACEUTICALS INC

    Hypercholesterolemia, Familial

    phase 2 small molecule completed

    1 trial

  21. ISIS 301012 or Placebo

    IONIS PHARMACEUTICALS INC

    Hypercholesterolemia

    phase 2 small molecule completed

    2 trials

  22. ISIS 416858

    IONIS PHARMACEUTICALS INC

    End-stage Renal Disease (ESRD)

    phase 2 small molecule completed

    2 trials

  23. ISIS 443139 10 mg

    IONIS PHARMACEUTICALS INC

    Huntington's Disease

    phase 2 small molecule completed

    1 trial

  24. ISIS 678354

    IONIS PHARMACEUTICALS INC

    Hypertriglyceridemia

    phase 2 small molecule completed

    1 trial

  25. ISIS 681257

    IONIS PHARMACEUTICALS INC

    Elevated Lipoprotein(a)

    phase 2 small molecule completed

    1 trial

  26. ISIS 702843

    IONIS PHARMACEUTICALS INC

    Polycythemia Vera

    phase 2 small molecule active

    1 trial

  27. ISIS 721744

    IONIS PHARMACEUTICALS INC

    Hereditary Angioedema

    phase 2 small molecule active

    1 trial

  28. ISIS 721744

    IONIS PHARMACEUTICALS INC

    Covid19

    phase 2 small molecule completed

    1 trial

  29. ISIS CRP Rx

    IONIS PHARMACEUTICALS INC

    Paroxysmal Atrial Fibrillation

    phase 2 small molecule completed

    1 trial

  30. ISIS CRP Rx or Placebo

    IONIS PHARMACEUTICALS INC

    Rheumatoid Arthritis

    phase 2 small molecule completed

    1 trial

  31. ISIS EIF4E Rx

    IONIS PHARMACEUTICALS INC

    Non-small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  32. ISIS EIF4E Rx

    IONIS PHARMACEUTICALS INC

    Castrate-Resistant Prostate Cancer

    phase 2 small molecule completed

    1 trial

  33. ISIS apoC-III Rx

    IONIS PHARMACEUTICALS INC

    Hypertriglyceridemia

    phase 2 small molecule completed

    1 trial

  34. ISIS-APO(a)Rx

    IONIS PHARMACEUTICALS INC

    Elevated Lipoprotein(a)

    phase 2 small molecule completed

    1 trial

  35. ISIS-APOCIIIRX

    IONIS PHARMACEUTICALS INC

    Type 2 Diabetes

    phase 2 small molecule terminated

    1 trial

  36. ISIS-FGFR4RX

    IONIS PHARMACEUTICALS INC

    Obesity

    phase 2 small molecule completed

    1 trial

  37. ISIS-FXIRx Dose #2

    IONIS PHARMACEUTICALS INC

    Venous Thromboembolism

    phase 2 small molecule completed

    1 trial

  38. ISIS-GCCRRx

    IONIS PHARMACEUTICALS INC

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  39. ISIS-GCGRRx

    IONIS PHARMACEUTICALS INC

    Type 2 Diabetes

    phase 2 small molecule completed

    1 trial

  40. ISIS-GCGRRx - Dose Level 1

    IONIS PHARMACEUTICALS INC

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  41. ISIS-GCGRRx- Dose Level 1

    IONIS PHARMACEUTICALS INC

    Type 2 Diabetes

    phase 2 small molecule completed

    1 trial

  42. ISIS-PTP1BRx

    IONIS PHARMACEUTICALS INC

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  43. IST-342

    Karyopharm Therapeutics Inc

    Relapsed Multiple Myeloma

    phase 2 small molecule terminated

    1 trial

  44. ITCC-054/AAML1921

    Disc Medicine

    Chronic Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  45. ITF2357

    Italfarmaco S.p.A.

    Duchenne muscular dystrophy (DMD)

    phase 2 small molecule active

    1 trial

  46. IV Remodulin

    United Therapeutics Europe Ltd

    Persistent Pulmonary Hypertension of the Newborn

    phase 2 small molecule terminated

    1 trial

  47. IVAMI

    Tour Hekla

    patients with stable coronary artery disease

    phase 2 small molecule active

    1 trial

  48. IVERMECTIN

    The George Institute

    Strongyloidiasis is caused by a parasite that is globally distributed in tropical and sub-tropical areas. Most patients with strongyloidiasis are asymptomatic or have mild symptoms with gastrointestinal disturbances, respiratory symptoms, and skin lesions. In situations of low defenses (patients under treatment with corticosteroids, organ transplant recipients or other situations) they can present serious complications with high mortality.

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.